The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains

Victor Ghetie, Andreas Engert, Roland Schnell, Ellen S. Vitetta

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

We have compared the in vitro and in vivo activities of three deglycosylated ricin A chain (dgA)-containing immunotoxins (ITs) with one versus two molecules of dgA per molecule of IgG. Two of the ITs (anti-CD19-dgA2 and anti-CD25-dgA2) had 3-0-fold improvements over their dgA1 counterparts in vitro. However, the in vivo anti-tumor activity of both constructs of each IT was the same. In contrast, anti-CD22-dgA2 was 7-fold more potent in vitro and significantly more potent in vivo than its dgA1 counterpart. These studies suggest that monoclonal antibodies must be individually tested to determine whether the addition of two versus one dgA will improve cytotoxic activity in vivo.

Original languageEnglish (US)
Pages (from-to)97-101
Number of pages5
JournalCancer Letters
Volume98
Issue number1
DOIs
StatePublished - Nov 27 1995

Keywords

  • CD19
  • CD22
  • CD25
  • Immunotoxin
  • Ricin A chain

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains'. Together they form a unique fingerprint.

  • Cite this